Everything below concerns heptapeptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-02-19. Numbers and descriptions here follow the published literature rather than marketing material.
Semax binds to melanocortin receptors and is thought to influence neuronal survival and plasticity rather than to act through the adrenal axis. Laboratory work has shown increased expression of brain-derived neurotrophic factor and nerve growth factor in treated tissue. Changes in c-Fos, a marker of neuronal activation, have also been reported. Because the peptide is rapidly degraded by peptidases, its effects are generally attributed to downstream signaling cascades rather than to sustained receptor occupancy.
Published studies are dominated by animal models of stroke, ischemia, and cognitive impairment, with a smaller number of human trials conducted in Russia. Many of the human reports are small, single-center, and published in Russian-language journals, which limits independent scrutiny. Outcome measures vary between studies and often rely on clinician-rated scales rather than objective biomarkers. Systematic reviews have noted the methodological weaknesses and called for larger, preregistered trials before firm conclusions can be drawn.
The proposed mechanism centres on neurotrophic signalling rather than direct receptor activation. Semax is reported to increase expression of brain-derived neurotrophic factor and nerve growth factor in several brain regions, and to shift the balance between excitatory and inhibitory neurotransmitter systems. Interaction with melanocortin receptors has been suggested because of the parent ACTH fragment. Many of these findings come from rodent studies, and the extent to which they translate to human physiology remains an open question.
Scientific literature on semax is unevenly distributed. A substantial share of published work originates from a small number of laboratories in Russia, while independent replication elsewhere is limited. Human data consist mostly of small trials with short follow-up, and several reported outcomes rely on subjective rating scales. Questions about how much intact peptide reaches the central nervous system after nasal administration, and how long it persists there, are still unresolved. The compound is best described as an active research subject rather than a settled pharmacological agent.
| Property | Value | Notes |
|---|---|---|
| Appearance | White lyophilized powder | Typical for synthetic peptides |
| Solubility | Freely soluble in water | Also soluble in saline |
| Storage temperature | -20 C or below | Protect from repeated freeze-thaw |
| Analytical method | Reverse-phase HPLC | Confirms purity and identity |
| Common synonym | ACTH(4-10) analog | Reflects structural origin |
Semax is normally supplied as a lyophilized powder, and that form is the most stable. Suppliers commonly recommend storage at -20 °C in a desiccated container protected from light, with short-term handling at room temperature limited to weighing and transfer. Powder that has absorbed moisture degrades faster, so vials should be warmed to ambient temperature before opening to prevent condensation on the contents. Hygroscopic behavior is typical of short hydrophilic peptides, and humidity control matters more than temperature alone for long-term retention.
Once dissolved, the peptide is considerably less stable than the solid. Aqueous solutions are usually prepared at neutral to slightly acidic pH, filtered, and divided into single-use aliquots before freezing. Repeated freeze-thaw cycles are a common cause of avoidable loss and are best prevented by never refreezing a thawed aliquot. Adsorption to plastic and glass surfaces can lower the measured concentration of dilute solutions, particularly below roughly 0.1 mg/mL. Buffer choice, salt content, and container material all influence how much peptide remains detectable after storage.
Identity and purity are established with standard peptide methods. Reversed-phase HPLC with ultraviolet detection near 214 nm resolves the parent peak from deletion and truncation byproducts, and reports typically quote a main-peak percentage. Mass spectrometry by electrospray or MALDI-TOF confirms the expected molecular mass, while amino acid analysis or peptide mapping can verify composition when the sequence itself is in question. A certificate of analysis that pairs a chromatogram with a mass spectrum is more informative than a purity figure alone. Counter-ion content and residual solvents are separate specifications and are frequently omitted.
Laboratory descriptions of the material are consistent across suppliers. It appears as a white to off-white lyophilized powder that dissolves readily in water and in polar organic solvents such as dimethyl sulfoxide. Aqueous solutions are clear and colorless at low concentrations. Because the peptide contains methionine, oxidation at the sulfur atom is a recognized degradation pathway, and handling notes usually call for protected, desiccated storage. Reported purity for research-grade lots is generally above 95 percent as measured by reversed-phase high-performance liquid chromatography.
The compound is registered in Russia as a pharmaceutical product, most commonly formulated as a nasal solution, and has been used in that setting since the 1990s. Outside that jurisdiction it is generally handled as a research chemical rather than an approved medicine. Regulatory status therefore differs sharply between countries, and material sold internationally may not correspond to the Russian pharmaceutical formulation. Documentation with commercial samples is typically limited to a certificate of analysis covering purity and identity, not clinical status or local legal classification.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It corresponds to the ACTH(4-7) fragment extended at the C-terminus by a Pro-Gly-Pro tripeptide, an addition intended to slow enzymatic breakdown. The molecular formula is C37H51N9O10S and the molecular mass is approximately 814 daltons. In the literature it is often described as an ACTH(4-10) analog, although that label reflects a naming convention as much as a precise structural relationship. The compound was developed in Russia and remains most closely associated with that research tradition.
Actinides seem to be a little less hard than lanthanides, probably due to a longer spatial extent of 5f atomic orbitals with respect to 4f ones, then a selective separation is possible thanks to ligands bearing soft donors such as nitrogen and sulfur atoms, by a different bonding nature compared to hard donors. Despite the potential separation of actinides, a direct extraction from the PUREX raffinate is very hard, due to the presence of many other interfering species in the feed such as activation and fission products. In this perspective, advanced separation processes involving very selective extracting agents are required to achieve an efficient partitioning for the following transmutation process. To sum up, knowledge of hydration, acid-base interactions, kinetics and thermodynamic stabilities and speciation of actinide and lanthanide ions with ligands is of great value to understand a solvent extraction process and to design new and promising extracting agents.
=== Healthcare === In July 2018, Premier Ford named Rueben Devlin, an orthopedic surgeon who was CEO of Toronto's Humber River Hospital and a "key Tory adviser" and former Ontario PCs president—to a $348,000 a year three-year appointment on the Council on Improving Healthcare and Ending Hallway Medicine, to curb hospital overcrowding. Devlin is the Ford family's "closest health-care adviser." Health costs in Ontario were over $60 billion annually, according to TVO's Steve Paikin. Devlin is tasked with the selection of the other Council members, and with "ending hallway medicine, dental care for seniors, improved mental-health services), all while ensuring stable, long-term funding for the system—Premier Ford's election promises. Since coming into power in June 2018, Premier Ford's government put an approved injection site in Toronto—and several other places—on pause while Health Minister Christine Elliott studied the issue. In February 2019, the Ontario NDP said that two sets of leaked documents show that the Ford government was creating a health "super agency" that "would be in charge of managing health services, quality improvement, patient relations, digital health and tissue donation and transplants, among other responsibilities." The documents said that "long-term care inspections" and the Ontario's "air ambulance service" Ornge would be "outsourced". According to a CTV News report, Minister Elliot was "forced to make assurances" that these services would not be "privatized".
== Scholarly works == Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis, Published in Travel Medicine and Infectious Disease, Volume 34, March–April 2020 Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), Published in The Journal of Medical Virology, Volume 92 Issue 7, July 2020 Probable Zoonotic Leprosy in the Southern United States, Published in the New England Journal of Medicine, April 28, 2011. ChikDenMaZika Syndrome: the challenge of diagnosing arboviral infections in the midst of concurrent epidemics, Published in Annals of Clinical Microbiology and Antimicrobials, Article 42, July 22, 2016. Lobomycosis in Venezuela, Published in the International Journal of Dermatology, Volume 46, Issue 22, February 2007. Venezuela's humanitarian crisis, resurgence of vector-borne diseases, and implications for spillover in the region, Published in The Lancet, Volume 19, Issue 5, May 2019.
== Research contributions == Balalaie's research focuses on several areas of organic chemistry, including environmentally friendly synthetic methods and pharmaceutical applications. His research group has worked on the development of multicomponent reactions (MCRs), particularly for the synthesis of heterocyclic compounds. His work in this area has included the use of zeolite catalysts for the preparation of tetrasubstituted imidazoles and other heterocycles. His research has also involved developing synthetic routes for several active pharmaceutical ingredients (APIs). Compounds published by his group include: Zoledronic acid, Gabapentin, Deferasirox and Pantoprazole. In peptide synthesis, Balalaie's work has included the synthesis of therapeutic peptides such as triptorelin, leuprolide, octreotide, and oxytocin. His group has also designed cyclopeptides containing heterocyclic structures (imidazole, thiazole, oxazole) intended to serve as potential anticancer agents. His book "Peptide Chemistry in Persian" was recognized as a winner of the Iran Book of the Year Award in 1399 (2020).
Sources: en.wikipedia.org
== Medical uses == Luspatercept is indicated for the treatment of adults with transfusion-dependent anemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy. Luspatercept is indicated for the treatment of adults with transfusion-dependent anaemia associated with beta thalassaemia.
== Identification in biological samples == A gas chromatography–mass spectrometry (GC–MS) method for the determination of fenethylline and related substances in plasma, urine, and hair has been developed, suggesting that hair testing can be useful for determining a drug history of fenethylline, and discrimination between fenethylline and its precursor, amphetamine.
== Biography == Edlich was admitted to Lafayette College at age 15 after finishing his sophomore year at Stuyvesant High School in New York City. Three years later, he enrolled as an early admission student at New York University School of Medicine. After graduating in 1970, he began a surgical residency at the University of Minnesota Health Sciences Center and received a Doctorate of Philosophy in Surgery.
Sources: en.wikipedia.org
It is associated with the melanocortin receptor family, particularly subtypes found in the central nervous system. This interaction is separate from the adrenal pathway activated by full-length ACTH.
Peptidases degrade the compound within minutes in circulation. This short half-life is one reason nasal delivery is used, placing the substance close to the olfactory and trigeminal pathways.
No large multicenter trials have been published in English-language journals. The existing human evidence consists mainly of smaller studies conducted in Russia, which limits generalization.
Semax is based on the ACTH(4-10) fragment, a seven-amino-acid segment of adrenocorticotropic hormone. The synthetic peptide retains the core sequence while removing regions associated with endocrine activity. This modification is intended to isolate effects on the nervous system.